Source: GlobeNewswire

Press Release: Xilio : Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the "Novel Immuno-Oncology" panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST.

Read full article »
Annual Revenue
$5.0-25M
Employees
25-100
Rene Russo's photo - CEO of Xilio

CEO

Rene Russo

CEO Approval Rating

90/100

Read more